Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.

@article{Olesen2011RisksOT,
  title={Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.},
  author={Jonas Bjerring Olesen and Gregory Y. H. Lip and Jesper Lindhardsen and Deirdre A Lane and Ole Ahlehoff and Morten Hansen and Jakob Rauns\o and Janne Schurmann Tolstrup and Peter Riis Hansen and Gunnar Hilmar Gislason and Christian Torp-Pedersen},
  journal={Thrombosis and haemostasis},
  year={2011},
  volume={106 4},
  pages={739-49}
}
It was the aim of this study to determine the efficacy and safety of vitamin K antagonists (VKAs) and acetylsalicylic acid (ASA) in patients with non-valvular atrial fibrillation (AF), with separate analyses according to predicted thromboembolic and bleeding risk. By individual level-linkage of nationwide registries, we identified all patients discharged with non-valvular AF in Denmark (n=132,372). For every patient, the risk of stroke and bleeding was calculated by CHADS₂, CHA₂DS₂-VASc, and… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation :
It was the aim of this study to determine the efficacy and safety of vitamin K antagonists ( VKAs ) and acetylsalicylic acid ( ASA ) in patients with non - valvular atrial fibrillation ( AF ) , with separate analyses according to predicted thromboembolic and bleeding risk .
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation :
It was the aim of this study to determine the efficacy and safety of vitamin K antagonists ( VKAs ) and acetylsalicylic acid ( ASA ) in patients with non - valvular atrial fibrillation ( AF ) , with separate analyses according to predicted thromboembolic and bleeding risk .
For every patient , the risk of stroke and bleeding was calculated by CHADS₂ , CHA₂DS₂-VASc , and HAS - BLED .
For every patient , the risk of stroke and bleeding was calculated by CHADS₂ , CHA₂DS₂-VASc , and HAS - BLED .
For every patient , the risk of stroke and bleeding was calculated by CHADS₂ , CHA₂DS₂-VASc , and HAS - BLED .
For every patient , the risk of stroke and bleeding was calculated by CHADS₂ , CHA₂DS₂-VASc , and HAS - BLED .
All Topics